Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.39 and traded as high as $2.43. Cumberland Pharmaceuticals shares last traded at $2.32, with a volume of 168,176 shares traded.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on Cumberland Pharmaceuticals in a research note on Friday. They set a “hold” rating for the company.
Read Our Latest Analysis on CPIX
Cumberland Pharmaceuticals Stock Down 2.2 %
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Recommended Stories
- Five stocks we like better than Cumberland Pharmaceuticals
- 3 Fintech Stocks With Good 2021 Prospects
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- What to Know About Investing in Penny Stocks
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.